127 related articles for article (PubMed ID: 31569625)
1. Synthesis and Evaluation of
Gibbens-Bandala B; Morales-Avila E; Ferro-Flores G; Santos-Cuevas C; Luna-Gutiérrez M; Ramírez-Nava G; Ocampo-García B
Polymers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569625
[TBL] [Abstract][Full Text] [Related]
2.
Gibbens-Bandala B; Morales-Avila E; Ferro-Flores G; Santos-Cuevas C; Meléndez-Alafort L; Trujillo-Nolasco M; Ocampo-García B
Mater Sci Eng C Mater Biol Appl; 2019 Dec; 105():110043. PubMed ID: 31546458
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells.
Jiménez-Mancilla N; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Luna-Gutiérrez M; Azorín-Vega E; Isaac-Olivé K; Camacho-López M; Torres-García E
J Labelled Comp Radiopharm; 2013 Nov; 56(13):663-71. PubMed ID: 25196028
[TBL] [Abstract][Full Text] [Related]
5. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of Lys¹(α,γ-Folate)Lys³(¹⁷⁷Lu-DOTA)-Bombesin(1-14) as a potential theranostic radiopharmaceutical for breast cancer.
Aranda-Lara L; Ferro-Flores G; Azorín-Vega E; Ramírez FM; Jiménez-Mancilla N; Ocampo-García B; Santos-Cuevas C; Isaac-Olivé K
Appl Radiat Isot; 2016 Jan; 107():214-219. PubMed ID: 26545016
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.
Carlucci G; Ananias HJ; Yu Z; Hoving HD; Helfrich W; Dierckx RA; Liu S; de Jong IJ; Elsinga PH
Mol Pharm; 2013 May; 10(5):1716-24. PubMed ID: 23590837
[TBL] [Abstract][Full Text] [Related]
8. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee Sy; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Feb; 42(2):131-6. PubMed ID: 25457455
[TBL] [Abstract][Full Text] [Related]
9. Preparation and in vitro evaluation of radiolabeled HA-PLGA nanoparticles as novel MTX delivery system for local treatment of rheumatoid arthritis.
Trujillo-Nolasco RM; Morales-Avila E; Ocampo-García BE; Ferro-Flores G; Gibbens-Bandala BV; Escudero-Castellanos A; Isaac-Olive K
Mater Sci Eng C Mater Biol Appl; 2019 Oct; 103():109766. PubMed ID: 31349410
[TBL] [Abstract][Full Text] [Related]
10. Assessment of
Vats K; Sharma R; Sharma AK; Sarma HD; Satpati D
J Pept Sci; 2022 Feb; 28(2):e3366. PubMed ID: 34463002
[TBL] [Abstract][Full Text] [Related]
11. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of [
Kumar N; Guleria M; Chakraborty A; Amirdhanayagam J; Bannore TU; Damle A; Sarma HD; Das T
Drug Dev Res; 2022 Dec; 83(8):1777-1790. PubMed ID: 36112735
[TBL] [Abstract][Full Text] [Related]
13. Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
Maina T; Kaloudi A; Valverde IE; Mindt TL; Nock BA
Nucl Med Biol; 2017 Sep; 52():57-62. PubMed ID: 28636973
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate.
Rogers BE; Manna DD; Safavy A
Cancer Biother Radiopharm; 2004 Feb; 19(1):25-34. PubMed ID: 15068608
[TBL] [Abstract][Full Text] [Related]
15. Fluorescent, Plasmonic, and Radiotherapeutic Properties of the
Mendoza-Nava H; Ferro-Flores G; Ramírez FM; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Luna-Gutiérrez M; Isaac-Olivé K
Mol Imaging; 2017 Jan; 16():1536012117704768. PubMed ID: 28654384
[TBL] [Abstract][Full Text] [Related]
16. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
[TBL] [Abstract][Full Text] [Related]
18. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215
[TBL] [Abstract][Full Text] [Related]
19. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
[TBL] [Abstract][Full Text] [Related]
20. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
Rogers BE; Bigott HM; McCarthy DW; Della Manna D; Kim J; Sharp TL; Welch MJ
Bioconjug Chem; 2003; 14(4):756-63. PubMed ID: 12862428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]